NCT04720534

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 229 (actual)
• Sponsor: Arrowhead Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.

Conditions

• Severe Hypertriglyceridemia

Interventions

Type	Name	Description
DRUG	ARO-APOC3	2 doses of ARO-APOC3 by subcutaneous (sc) injection
DRUG	Placebo	calculated volume to match active treatment by sc injection

Timeline

• Start date: 2021-05-31
• Primary completion: 2023-03-09
• Completion: 2023-08-31
• First posted: 2021-01-22
• Last updated: 2026-03-24
• Results posted: 2026-03-24

Locations

74 sites across 8 countries: United States, Australia, Canada, Germany, Hungary, Netherlands, New Zealand, Poland

Regulatory

• FDA-regulated drug study